[1] Gross G,Waks T,Eshhar Z.Expression of immunoglobulin- T-cell receptor chimeric molecules as functional receptorswith antibody-type specificity.Proc Natl Acad Sci U S A.1989; 86(24):10024-10028.[2] Kalos M,Levine BL,Porter DL,et al.T cells with chimeric antigenreceptors have potent antitumor effocts and can establish lllelllory inpatients with advanced leukemia. Sci Transl Med.2011;3:95ra73.[3] Pulè MA,Straathof KC,Dotti G,et al.A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human Tcells.Mol Ther.2005;12(5): 933-941.[4] Till BG,Jensen MC,Wang J,et al.CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results.Blood.2012;9(17):3940-3950.[5] Pegram HJ,Lee JC,Hayman EG,et al.Tumor-targeted T cellsmodified to secrete IL-12 eradicate systemic tumors without needfor prior conditioning.Blood.2012;119(18): 4133-4141.[6] Rushworth D,Jena B,Olivares S,et al.Universal artificial antigen presenting cells to selectively propagate T cells expressing chimeric antigen receptor in dependent of specificity.J Immunother.2014;37(4):204-213. [7] Chmielewski M,Hombach AA,Abken H.Of CARsand TRUCKs: chimeric antigen receptor(CAR) T cellsengineered with an inducible cytokine to modulate thetumor stroma.Immunol Rev. 2014;257(1):83-90.[8] 陈青,白定群.光化学转染对肿瘤治疗的研究进展[J].世界复合医学,2015,1(2):162-167.[9] Spear P,Barber A,Rynda Apple A,et al.Chimericantigen receptor t cells shape myeloid cell function within the tumor microenvironment through IFN-r and GM-CSF.J Immunol. 2012; 188(12):6389-6398. [10] Kochenderfer JN,Dudley ME,Kassim SH,et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cellmalignancies can be effectively treated with autologous T cellsexpressing an anti-CDl9 chimeric antigen receptor.J Clin Oncol 2015;33(6):540.[11] Cartellieri M,Koristika S,Arndt C,et al.A novel ex vivo isolation and expansion procedure for chimeric antigen receptor engrafted human T cells.PLoS One.2014;9(4):e93745.[12] Kochendetier JN,Wilson WH,Janik JE,et al.Eradication of B-lineage cells and regression of lymphoma in a patient treated withautologous T cells genetically enoneered to recognize CDl9.Blood.2010;116(20):4099-4102.[13] Beatty GL,Haas AR,Maus MV,et al.Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies.Cancer Immunol Res.2014;2(2):112-120.[14] Kochendeffer JN,Dudley ME,Feldman SA,et al.B-cell depletion andremissions of malignancy along with cytokine-associated toxicity in aclinical trial of anti-CDl9 chimeric-antigen-recepto-transduced Tcells.Blood.2012; 119:2709-2720.[15] Porter DL,Kalos M,Frey NV,et al.Chimeric antigen receptormodified T cells directed against CDl9(CTL019 cells) have long-termpersistence and induce durable responses in relapsed, refl'actocr CLL.Blood.2014; 122(21):4162.[16] Grupp SA,Frey NV,Aplenc R,et al.T cells engineered withachimericantigenreceptor(CAR)targetingCDl9(CTL019)produce significant in vivo proliferation,complete responsesand long-term persistence without gvhd in children and adultswith relapsed,refractory ALL(abstracts).Blood.2013;122:67.[17] Lee DW,Kochenderfer JN,Stetler-Stevenson M,et al.T cellsexpressing CD 19 chimeric antigen receptors for acutelymphoblastic leukaemia in children and young adults: a phase 1dose-escalation trial.Lancet.2015;385(9967): 517-528.[18] Brentjens RJ,Davila ML,Riviere I,et al.CD19-targeted Tcellsrapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia.Sci Transl Med.2013;5:177ra38.[19] Grupp SA.Chimeric antigen receptor-modified T cells for acute lymphoid leukemia.N Engl J Med.2013;368(16): 1509-1518. [20] Kochendeffer JN,Dudley ME,Kassim SH,et al.Effoctive treatment ofchemotherapy-refractocr diffuse large B-cell lymphoma withautologous T cells genetically-engineered to express an anti-CDl9 chimeric antigen receptor.ASH.2013; 122(7):168-168.[21] Zhong XS.Chimeric antigen receptors combining 4-1BB andCD28 signaling domains augment PI3kinase/AKT/Bcl-XL activationand CD8+ T cell-mediated tumor eradication.Mol Ther.2010;18(2):413-420.[22] Zhou X,Di Stasi A,Tey SK,et al.Long-term outcome afterhaploidentical stem cell transplant and infusion of T cellsexpressing the inducible caspase 9 safety transgene. Blood.2014;123(25):3895-3905.[23] 何红晨,徐月萌,熊恩富,等.浅谈国际康复医学发展及启示[J].世界复合医学,2015,1(2): 130-133.[24] Giordano Attianese GM.In vitro and in vivo model of a novelimmunotherapy approach for chronic lymphocytic leukemia byanti-CD23 chimeric antigen receptor.Blood.2011; 117(18):4736-4745.[25] Hudecek M.The B-cell tumor-associated antigen ROR1 can betargeted with T cells modified to express a ROR1-specific chimericantigen receptor.Blood.2010;116(22): 4532-4541.[26] Pegram HJ.Tumor-targeted T cells modified to secrete IL-12eradicate systemic tumors without need for prior conditioning.Blood.2012;119(18):4133-4141.[27] Lee WL,Slutsky AS.Sepsis and endothelial permeability.N EnglJ Med.2010;363(7):689-691.[28] Xu XJ,Tang YM.Cytokine release syndrome in cancer immune-therapy with chimeric antigen receptor engineered T cells.Cancer Lett.2014;343(2):172-178.[29] 李伟,于慧杰,江其生.嵌合抗原受体修饰的T细胞免疫治疗研究进展[J].肿瘤研究与临床,2015,27(2):139-141.[30] Carpenito C,Milone MC,Hassan R,et al.Control of large, established tumor xenografts with genetically retargeted human T cellscontaining CD28 and CD137 domains.Proc Natl Acad Sci U S A.2009;106(9):3360-3365.[31] Tettamanti S,Marin V,Pizaaitola I,et al.Targeting of acute myeloid leukemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor.Br J Haematol.2013;161(3):389-401.[32] Lynn RC,Poussin M,Kalota A,et al.Targeting of folatereceptor p on acute myeloid leukemia blasts with chimericantigen receptor-expressing T cells.Blood.2015;125(22): 3466-3476.[33] Kanagawa N,Yanagawa T,Nakagawa T,et al.Tumor vessel-injuringability improves antitumor effect of cytotofic T lymphocytes inadoptive immunotherapy.Cancer Gene. 2013; 20(1):57-64.[34] Naumann A,Kim Y,Kfinigs C,et al.Generation andcharacterization of FVIII specific CAR-transduced regulatory T cells.Blood(ASH annual meeting Abstracts). 2014;124(21):236.[35] Pegram HJ,Park JH,Brentjens RJ.CD28z CARs and armored CARs.Cancer J.2014;20(2):127-133.[36] Gill S,June CH.Going viral:chimeric antigen receptor T-cell therapy for hematological malignancies.Immunol Rev.2015; 263(1):68-89.[37] 袁顺宗,苏航.利用嵌合抗原受体的T细胞(CAR-T)治疗复发和难治B细胞淋巴瘤/白血病的转化医学研究[J].中国实验血液学杂志,2014,22(4):1137-1141.[38] Ma Q,Gomes EM,Lo AS,et al.Advanced generation anti-prostate specific membrane antigen designer T cells for prostate cancerimmunotherapy.Prostate.2014;74(3):286-296. [39] Casucci M,Hawkins RE,Dotti G,et al.Overcoming the toxicityhurdles of genetically targeted T cells.Cancer Immunol Immunother.2015;64(1):123-130.[40] Maude SL,Teachey DT,Porter DL,et al.CD1 9-targetedchimeric antigen receptor T-cell therapy for acute lymphoblasticleukemia.Blood.2015;125(26):4017-4023.[41] Hillerdal V,Ramachandran M,Leja J,et al.Aystemic treatment with CAR-engineeredTcells against PSCA delays subcutaneous tumor growtj and prolongs survival of mice. BMC Cancer.2014;14(1):30-39. [42] Abate-Daga D,Lagisetty KH,Tran E,et al.A novel chimericantigen receptor againstprostate sem cell antigen mediates tumor destruction in a humanized mouse model of pancreatic.Cancer.Hum Gene Ther.2014;25(12):209-219. [43] Miao HS,Choi BD,Suryadevara CM,et al.EGFR Viii-specific chimeric antigen receptor T cells migrate to and kill tumor deposits infiltrating the brain parenchyma in an in vasive xenograftmodelofglioblastoma.PLoS One.2014;9(4):e94281.[44] Zhang G,Wang L,Cui H,et al.Anti-melanoma activity of T cells redirected withaTCR-like chimeric antigen receptor.Sci Rep. 2014;4(1):3571. [45] Rosenberg SA,Restifo NP.Adoptive cell transfer as personalizedimmunotherapy for human cancer.Science. 2015;348(6230):62-68.[46] Sentman CL,Meehan KR.NKG2D CARs as cell therapy for cancer.Cancer J.2014;20(2):156-159. [47] Wang LC,Lo A,Scholler J,et al.Targeting fibroblast activation proteinin tumor stroma with chimeric antigen recetor T cells can inhibit tumor growth and augment host immunity without severe toxicity.Cancer Immunol Res.2014;2(2):154-166. [48] Hong H,Stastny M,Brown C,et al.Diverse solid tumors expressing a restricted epitope of L1-CAM can be targeted by chimeric antigen receptor redirected T lymphocytes.J Immunother.2014;37(2):94-104. [49] Chen MY.New PLA General Hospital released CART therapy phaseI clinical data. Biodiscover.com, 2015-05-27 [2015-05-27].http://www.biodiscover.com/news/politics/119184.html. |